VC
KRTX

Vivo Capital’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Vivo Capital’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-223,692
Closed -$16.1M – 59
2020
Q1 		$16.1M Buy
+223,692
New +$19.1M 1.46% 19
2019
Q3 		– Sell
-325,000
Closed -$6.51M – 34
2019
Q2 		$6.51M Buy
+325,000
New +$6.51M 0.61% 34

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Vivo Capital's KRTX Position: Q2 2020 in Review

Vivo Capital sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2020, closing a stake of 223,692 shares — an estimated $16.1M sold.

Vivo Capital first reported a position in KRTX in Q2 2019 and held it in 2 quarters. The position peaked at $16.1M in Q1 2020. 130 funds tracked by Wall St. Rank hold KRTX as of Q2 2020.

  • Vivo Capital reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Vivo Capital sold 223,692 Karuna Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $16.1M.
  • Vivo Capital first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2019 and held it in 2 quarters.
  • Vivo Capital's Karuna Therapeutics, Inc. Common Stock position peaked at $16.1M in Q1 2020.
  • 130 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Vivo Capital's 13F filing for Q2 2020, filed 14 Aug 2020.